LFCR
LIFECORE BIOMEDICAL, INC. DE
$4.57
+4.34%
$164.3M
No data for this timeframe.
Vol
Market Cap$164.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (73%)
Inst. Holders7 funds
Inst. Value$21.3M
Inst. Activity3 buys / 0 sells
Reddit Sentiment67° Warm
SEC Reports1
Press Releases3
Recent Activity
May 6, 2026
SEC
Lifecore Biomedical reported Q1 2026 revenue of $23.2M, a 34% decline YoY from $35.2M, and a net loss of $15.0M ($0.43/s
8-K — Impact 7/10
Apr 14, 2026
Insider
Salus Thomas D. sold 24,645 shares
Chief Legal & Administration @ $5.20 ($128.2K)
Mar 2, 2026
Insider
Salus Thomas D. sold 30,000 shares
Chief Legal & Administration @ $0.00 ($0.00)
Inst.
WELLS FARGO & COMPANY/MN — ADD
30,757 shares ($251.6K)
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
27,803 shares ($227.4K)
May 6, 2026
earnings
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update
Lifecore's Q1 2026 Earnings
Mar 26, 2026
Press
Lifecore Biomedical announced two new CDMO manufacturing agreements with an existing U.S. biopharmaceutical customer: on
Impact 7/10
Mar 16, 2026
Press
Lifecore Biomedical reported strong financial results for the seven-month transition period ending December 31, 2025, wi
Impact 6/10
Price Targets
$6.67
+45.9% upside
Strong Buy
Current $4.57
Low $5.00
Median $6.00
High $9.00
3 analysts
$5.00
$9.00
Analyst Ratings
4Strong Buy
4Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 29, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 27, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 24, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 17, 2026 | Barrington Research | UPGRADE | Market Perform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.22 ▼ -4.7% | $-0.30 — $-0.17 | 4 | |
| Next Q | $-0.22 ▲ +6.5% | $-0.29 — $-0.11 | 4 | |
| Current FY | $-1.04 ▼ -17.4% | $-1.22 — $-0.97 | -94% YoY | 4 |
| Next FY | $-0.98 ▼ -13.2% | $-1.13 — $-0.83 | 6% YoY | 4 |
Latest Reports
BEARISH
8-K
7/10
Lifecore Biomedical reported Q1 2026 revenue of $23.2M, a 34% decline YoY from $35.2M, and a net loss of $15.0M ($0.43/s
May 6, 2026
BULLISH
Press
7/10
Lifecore Biomedical announced two new CDMO manufacturing agreements with an existing U.S. biopharmaceutical customer: on
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $13.7M | — |
| MORGAN STANLEY | $6.1M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $717.5K | NEW |
| WELLS FARGO & COMPANY/MN | $251.6K | ADD |
| TWO SIGMA INVESTMENTS, LP | $227.4K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 14, 2026 | Salus Thomas | F | $128.2K |
| Mar 2, 2026 | Salus Thomas | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $21.3M total value (2,601,014 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,673,666 | $13.7M | 64.3% | — |
| 2 | MORGAN STANLEY | 751,505 | $6.1M | 28.9% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 87,713 | $717.5K | 3.4% | NEW |
| 4 | WELLS FARGO & COMPANY/MN | 30,757 | $251.6K | 1.2% | ADD +69.7% |
| 5 | TWO SIGMA INVESTMENTS, LP | 27,803 | $227.4K | 1.1% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 26,337 | $215.4K | 1.0% | ADD +52.4% |
| 7 | FMR LLC | 3,233 | $26.4K | 0.1% | ADD +29.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | ADD | 18,125 | 30,757 | +69.7% | $251.6K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 27,803 | — | $227.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 17,284 | 26,337 | +52.4% | $215.4K | 2025-Q4 |
| FMR LLC | ADD | 2,417 | 3,139 | +29.9% | $25.5K | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 31,923 | — | $224.7K | 2025-Q1 |
| UBS Group AG | DOUBLED | 36,091 | 108,981 | +202.0% | $809.7K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 10,369 | 13,381 | +29.0% | $99.4K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 60,505 | — | $298.3K | 2024-Q3 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 14, 2026 | Salus Thomas D. | Chief Legal & Administration | F | 24,645 | $5.20 | $128.2K |
| Mar 2, 2026 | Salus Thomas D. | Chief Legal & Administration | A | 30,000 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
BULLISH
7/10
Lifecore Biomedical announced two new CDMO manufacturing agreements with an existing U.S. biopharmac
Mar 26, 2026
MIXED
6/10
Lifecore Biomedical reported strong financial results for the seven-month transition period ending D
Mar 16, 2026
NEUTRAL
4/10
Lifecore Biomedical (LFCR) has entered into a new development services agreement with Indomo to manu
Mar 4, 2026
Current analyst consensus: Buy (73% buy). Based on 11 analysts: 4 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.67 mean target
+45.9% upside
Strong Buy (2.00)
$5.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $4.57 |
| Target Low | $5.00 |
| Target Mean | $6.67 |
| Target Median | $6.00 |
| Target High | $9.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.22 | $-0.30 | $-0.17 | — | -4.7% | 2↑ 1↓ | $0.0B | — | 4 |
| Next Q 2026-09-30 |
$-0.22 | $-0.29 | $-0.11 | — | +6.5% | 0↑ 1↓ | $0.0B | — | 4 |
| Current FY 2026-12-31 |
$-1.04 | $-1.22 | $-0.97 | -93.5% | -17.4% | 0↑ 3↓ | $0.1B | 61.8% | 4 |
| Next FY 2027-12-31 |
$-0.98 | $-1.13 | $-0.83 | 5.7% | -13.2% | 0↑ 2↓ | $0.1B | 6.6% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.223 | |
| 7d ago | $-0.212 | -0.010 |
| 30d ago | $-0.212 | -0.010 |
| 60d ago | $-0.220 | -0.003 |
| 90d ago | $-0.220 | -0.003 |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 29, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 27, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 24, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 17, 2026 | Barrington Research | UPGRADE | Market Perform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Feb 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Jan 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 6, 2026
earnings
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update
Lifecore's Q1 2026 Earnings
May 6, 2026
earnings_calendar
LFCR Q1 2026 Earnings After Market Close — 2026-05-06
Apr 22, 2026
other
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore announces inducement grant
Apr 8, 2026
other
Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
Apr 8, 2026
earnings_calendar
LFCR Q3 2026 Earnings Scheduled — 2026-04-08
Mar 26, 2026
other
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 26, 2026
contract
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
Mar 23, 2026
contract
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
Mar 16, 2026
earnings
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
Lifecore Biomedical Q4 and Transition Period 2025 Earnings Results
Mar 10, 2026
other
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
Mar 9, 2026
earnings
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
Mar 4, 2026
contract
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Lifecore Biomedical and Indomo sign new agreement to support innovative drug/device combination acne treatment.